Key Takeaways
- • MDB Capital Holdings (NASDAQ: MDBH) reported fee income up 96% to $4.2 million for the nine months ended September 30, 2026, versus $2.1 million a year earlier.
- • The company ended the quarter with $8.3 million in cash and cash equivalents as of September 30, 2026, and kept total operating expenses flat versus both the prior year and prior quarter.
- • MDB is focusing on four "Big Ideas": Public Ventures, PatentVest, eXoZymes (NASDAQ: EXOZ), and Paulex Bio, with the Board reviewing structures to share value realized with shareholders.
- • PatentVest is pursuing financing to become an independent company in 2027, and Public Ventures is in talks about expanding its self-clearing platform, possibly as a standalone launch.
- • Management is pursuing external funding and reducing costs with the stated goal of minimizing shareholder dilution; CEO Christopher Marlett hosts a Zoom webinar at 4:30 p.m. ET on November 17, 2026.
Summary
On the business side, MDB said Public Ventures is in discussions with potential strategic and capital partners to expand the reach of its self-clearing platform, including a potential launch independent of MDB. PatentVest, the company's intellectual property law firm, is pursuing financing to grow its client base and expand marketing ahead of becoming an independent company in 2027. At eXoZymes (Nasdaq: EXOZ), the company selected Curia as its first commercial-scale manufacturing partner to support technology transfer and scale-up of NCT, and announced new compounds with large market potential. Paulex Bio announced the registration of a first-in-human Phase 1/2a trial of PAL-119, an investigational oral drug candidate targeting the root cause of Type 1 and Type 2 diabetes, designed to evaluate safety and tolerability and explore beta cell expansion.
Financially, fee income rose 96% to $4.2 million for the nine months ended September 30, 2026, from $2.1 million a year earlier. Cash and cash equivalents totaled $8.3 million at quarter-end, and total operating expenses were flat compared with both the prior year and the prior quarter. MDB said it is pursuing external funding and partnerships for Public Ventures and PatentVest with the goal of minimizing dilution to shareholders. The Board is reviewing potential structures for sharing any value realized with shareholders as these businesses reach key milestones.
MDB will host a Zoom webinar at 4:30 p.m. ET on November 17, 2026, led by CEO and co-founder Christopher Marlett, to review recent developments and hold a question-and-answer session. MDB Capital is a registered broker-dealer and FINRA/SIPC member, and the company's release includes standard forward-looking statement cautions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.